Gemcitabine-based chemotherapy as a viable option for treatment of advanced breast cancer patients: a meta-analysis and literature review.

about

Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer

P2860

Q57106074-F7861468-2D81-4452-BB3B-C6B12F6B3B8A

P2860

Gemcitabine-based chemotherapy as a viable option for treatment of advanced breast cancer patients: a meta-analysis and literature review.

Item

http://www.wikidata.org/entity/Q50221869

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Gemcitabine-based chemotherapy ...... nalysis and literature review.

@en

Gemcitabine-based chemotherapy ...... nalysis and literature review.

@nl

type

Item

label

Gemcitabine-based chemotherapy ...... nalysis and literature review.

@en

Gemcitabine-based chemotherapy ...... nalysis and literature review.

@nl

prefLabel

Gemcitabine-based chemotherapy ...... nalysis and literature review.

@en

Gemcitabine-based chemotherapy ...... nalysis and literature review.

@nl

P1476

Gemcitabine-based chemotherapy ...... nalysis and literature review.

@en

P2093

Chen Jin

http://www.w3.org/2001/XMLSchema#string

Deliang Fu

http://www.w3.org/2001/XMLSchema#string

Yifan Zhang

http://www.w3.org/2001/XMLSchema#string

Zhibo Xie

http://www.w3.org/2001/XMLSchema#string

P2860

Single agent versus combination chemotherapy for metastatic breast cancer

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Global cancer statistics, 2012

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Practical methods for incorporating summary time-to-event data into meta-analysis

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

Updated method guidelines for systematic reviews in the cochrane collaboration back review group

Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized p

A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer.

P304

7148-7161

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.23426

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29467957

http://www.w3.org/2001/XMLSchema#string

P932

5805543

http://www.w3.org/2001/XMLSchema#string

Gemcitabine-based chemotherapy as a viable option for treatment of advanced breast cancer patients: a meta-analysis and literature review.

about

P2860

P2860

Gemcitabine-based chemotherapy as a viable option for treatment of advanced breast cancer patients: a meta-analysis and literature review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932